Protein misfolding, aggregation, and degradation in disease

Molecular Biotechnology

Volumn 31, Issue 2, 2005, Pages 141-150

  Gregersen, Niels ^a   Bolund, Lars ^a   Bross, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Conformational disease; Protein aggregation; Protein aggregation diseases; Protein folding; Protein misfolding; Protein quality control

Indexed keywords

CONFORMATIONS; DISEASES; GENES; PATHOLOGY;

CONFORMATIONAL DISEASE; PROTEIN AGGREGATION; PROTEIN AGGREGATION DISEASES; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN QUALITY CONTROL;

AGGLOMERATION;

AMINO ACID; CHAPERONE; COLLAGEN; KERATIN; PROTEINASE;

ALZHEIMER DISEASE; COLLAGEN DISEASE; DEGENERATIVE DISEASE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GENERAL ASPECTS OF DISEASE; HEREDITY; METABOLIC DISORDER; MOLECULAR BIOLOGY; OXIDATIVE STRESS; PATHOGENESIS; PATHOLOGY; PHENYLKETONURIA; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; QUALITY CONTROL; REVIEW; TOXICOLOGY;

AMINO ACIDS; ANIMALS; DISEASE; HUMANS; PROTEIN CONFORMATION; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEINS;

EID: 24944456875     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:31:2:141     Document Type: Review

References (68)

1. Carrell, R. W. and Lomas, D. A. (1997) Conformational disease. Lancet 350, 134-138.
2. Carrell, R. W. and Lomas, D. A. (2002) Alpha1-antitrypsin deficiency - a model for conformational diseases. N. Engl. J. Med. 346, 45-53.
3. Crowther, D. C. (2002) Familial conformational diseases and dementias. Hum. Mutat. 20, 1-14.
4. Sorensen, C. B., Ladekjaer-Mikkelsen, A. S., Andresen, B. S., et al. (1999) Identification of novel and known mutations in the genes for keratin 5 and 14 in Danish patients with epidermolysis bullosa simplex: correlation between genotype and phenotype. J. Invest Dermatol. 112, 184-190.
5. Baum, J. and Brodsky, B. (1999) Folding of peptide models of collagen and misfolding in disease. Curr. Opin. Struct. Biol. 9, 122-128.
6. Burch, M. and Blair, E. (1999) The inheritance of hypertrophic cardiomyopathy. Pediatr. Cardiol. 20, 313-316.
7. Monti, P., Campomenosi, P., Ciribilli, Y., et al. (2002) Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene 21, 1641-1648.
8. Bross, P., Corydon, T. J., Andresen, B. S., Jørgensen, M. M., Bolund, L., and Gregersen, N. (1999) Protein misfolding and degradation in genetic diseases. Hum. Mutat. 14, 186-198.
9. Gregersen, N., Bross, P., Andresen, B. S., Pedersen, C. B., Corydon, T. J., and Bolund, L. (2001) The role of chaperone-assisted folding and quality control in inborn errors of metabolism: protein folding disorders. J. Inherit. Metab. Dis. 24, 189-212.
10. Waters, P. J. (2001) Degradation of mutant proteins, underlying "loss of function" phenotypes, plays a major role in genetic disease. Curr. Issues Mol. Biol. 3, 57-65.
11. Riordan, J. R. (1999) Cystic fibrosis as a disease of misprocessing of the cystic fibrosis transmembrane conductance regulator glycoprotein. Am. J. Hum. Genet. 64, 1499-1504.
12. Waters, P. J., Parniak, M. A., Akerman, B. R., and Scriver, C. R. (2000) Characterization of phenylketonuria missense substitutions, distant from the phenylalanine hydroxylase active site, illustrates a paradigm for mechanism and potential modulation of phenotype. Mol. Genet. Metab. 69, 101-110.
13. Waters, P. J. (2003) How PAH gene mutations cause hyper-phenylalaninemia and why mechanism matters: insights from in vitro expression. Hum. Mutat. 21, 357-369.
14. Perlmutter, D. H. (1999) Misfolded proteins in the endoplasmic reticulum. Lab. Invest. 79, 623-638.
15. Gregersen, N., Andresen, B. S., Corydon, M. J., et al. (2001) Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum. Mutat. 18, 169-189.
16. Gregersen, N., Bross, P., and Andresen, B. S. (2004) Genetic defects in fatty acid beta-oxidation and acyl-CoA dehydrogenases. Eur. J. Biochem. 271, 470-482.
17. Bross, P. and Gregersen, N. (2003) Protein Misfolding and Disease - Principles and Protocols. Humana, Totowa, NJ.
18. Uversky, V. N. (2002) Natively unfolded proteins: a point where biology waits for physics. Protein Sci. 11, 739-756.
19. Barral, J. M., Broadley, S. A., Schaffar, G., and Hartl, F. U. (2004) Roles of molecular chaperones in protein misfolding diseases. Semin. Cell Dev. Biol. 15, 17-29.
20. Gregersen, N., Bross, P., and Jørgensen, M. M. Chapter 13.1: Protein folding and misfolding: The role of cellular protein quality control systems in inherited disorders. In: MMBID - ONLINE (Scriver, C. R., Beaudet, A. L., Valle, D., Sly, W. S., Vogelstein, B., Childs, B., and Kinzler, K. W., eds.), McGraw-Hill, New York, URL: http://genetics.accessmedicine.com.
21. Cooper, D. N. and Krawczak, M. (1993) Human Gene Mutation. Bios Scientific Publishers, Ltd., Oxford, UK.
22. Krawczak, M., Ball, E. V., Fenton, I., et al. (2000) Human gene mutation database - a biomedical information and research resource. Hum. Mutat. 15, 45-51.
23. Cartegni, L., Chew, S. L., and Krainer, A. R. (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nut. Rev. Genet. 3, 285-298.
24. Milewski, M. I., Mickle, J. E., Forrest, J. K., Stanton, B. A., and Cutting, G. R. (2002) Aggregation of misfolded proteins can be a selective process dependent upon peptide composition. J. Biol. Chem. 277, 34462-34470.
25. Johnston, J. A., Ward, C. L., and Kopito, R. R. (1998) Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143, 1883-1898.
26. Pedersen, C. B., Bross, P., Winter, V. S., et al. (2003) Misfolding, Degradation, and aggregation of variant proteins: the molecular pathogenesis of short chain acyl-CoA dehydrogenase (SCAD) deficiency. J. Biol. Chem. 278, 47449-47458.
27. Vladutiu, G. D. (1999) Biochemical and molecular correlations in carnitine palmitoyltransferase II deficiency. Muscle Nerve 22, 949-951.
28. Sorensen, C. B., Ladekjaer-Mikkelsen, A. S., Andresen, B. S., et al. (1999) Identification of novel and known mutations in the genes for keratin 5 and 14 in Danish patients with epidermolysis bullosa simplex: correlation between genotype and phenotype. J. Invest Dermatol. 112, 184-190.
29. Dobson, C. M. (2001) The structural basis of protein folding and its links with human disease. Philos. Trans. R. Soc. Lond B Biol. Sci. 356, 133-145.
30. Wu, Y., Whitman, I., Molmenti, E., Moore, K., Hippenmeyer, P., and Perlmutter, D. H. (1994) A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc. Natl. Acad. Sci. USA 91, 9014-9018.
31. Lomas, D. A., Evans, D. L., Finch, J. T., and Carrell, R. W. (1992) The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 357, 605-607.
32. Perutz, M. F. (1999) Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sci. 24, 58-63.
33. Mattson, M. P., Chan, S. L., and Duan, W. (2002) Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol. Rev. 82, 637-672.
34. Taylor, J. P., Hardy, J., and Fischbeck, K. H. (2002) Toxic proteins in neurodegenerative disease. Science 296, 1991-1995.
35. Zoghbi, H. Y. and Botas, J. (2002) Mouse and fly models of neurodegeneration. Trends Genet. 18, 463-471.
36. Chiti, F., Taddei, N., Baroni, F., et al. (2002) Kinetic partitioning of protein folding and aggregation. Nat. Struct. Biol. 9, 137-143.
37. Soto, C. (2001) Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 498, 204-207.
38. Bucciantini, M., Giannoni, E., Chiti, F., et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
39. Walsh, D. M., Klyubin, I., Fadeeva, J. V., et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
40. Kayed, R., Head, E., Thompson, J. L., et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489.
41. Teckman, J. H. and Perlmutter, D. H. (2000) Retention of mutant alpha(1)-antitrypsin Z in endoplasmic reticulum is associated with an autophagic response. Am. J. Physiol Gastrointest. Liver Physiol. 279, G961-G974.
42. Earl, R. T., Mangiapane, E. H., Billett, E. E., and Mayer, R. J. (1987) A putative protein-sequestration site involving intermediate filaments for protein degradation by autophagy. Studies with transplanted Sendai-viral envelope proteins in HTC cells. Biochem. J. 241, 809-815.
43. Weihofen, A., Binns, K., Lemberg, M. K., Ashman, K., and Martoglio, B. (2002) Identification of signal peptide peptidase, a presenilin-type aspartic protease. Science 296, 2215-2218.
44. Yang, Y., Turner, R. S., and Gaut, J. R. (1998) The chaperone BiP/GRP78 binds to amyloid precursor protein and decreases Abeta40 and Abeta42 secretion. J. Biol. Chem. 273, 25552-25555.
45. Weber, A. J., Soong, G., Bryan, R., Saba, S., and Prince, A. (2001) Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am. J. Physiol Lung Cell Mol. Physiol. 281, L71-L78.
46. Zhao, Q., Wang, J., Levichkin, I. V., Stasinopoulos, S., Ryan, M. T., and Hoogenraad, N. J. (2002) A mitochondrial specific stress response in mammalian cells. EMBO J. 21, 4411-4419.
47. Uversky, V. N., Lee, H. J., Li, J., Fink, A. L., and Lee, S. J. (2001) Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem. 276, 43495-43498.
48. Beal, M. F. (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 23, 298-304.
49. Butterfield, D. A. and Kanski, J. (2001) Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech. Ageing Dev. 122, 945-962.
50. Bence, N. F., Sampat, R. M., and Kopito, R. R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555.
51. Imaizumi, K., Miyoshi, K., Katayama, T., et al. (2001) The unfolded protein response and Alzheimer's disease. Biochim. Biophys. Acta 1536, 85-96.
52. Martindale, J. L. and Holbrook, N. J. (2002) Cellular response to oxidative stress: signaling for suicide and survival. J. Cell Physiol. 192, 1-15.
53. Hughes, R. E. (2002) Polyglutamine disease: acetyltransferases awry. Curr. Biol. 12, R141-R143.
54. Schaffar, G., Breuer, P., Boteva, R., et al. (2004) Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 15, 95-105.
55. Dukan, S., Farewell, A., Ballesteros, M., Taddei, F., Radman, M., and Nystrom, T. (2000) Protein oxidation in response to increased transcriptional or translational errors. Proc. Natl. Acad. Sci. USA 97, 5746-5749.
56. Gamez, A., Perez, B., Ugarte, M., and Desviat, L. R. (2000) Expression analysis of phenylketonuria mutations. Effect on folding and stability of the phenylalanine hydroxylase protein. J. Biol. Chem. 275, 29,737-29,742.
57. Pind, S., Riordan, J. R., and Williams, D. B. (1994) Participation of the endoplasmic reticulum chaperone calnexin (P88, Ip90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269, 12784-12788.
58. Qu, D. F., Teckman, J. H., Omura, S., and Perlmutter, D. H. (1996) Degradation of a mutant secretory protein, alpha(1)- antitrypsin Z, in the endoplasmic reticulum requires proteasome activity. J. Biol. Chem. 271, 22791-22795.
59. Soti, C. and Csermely, P. (2000) Molecular chaperones and the aging process. Biogerontology 1, 225-233.
60. Macario, A. J. and Conway de, M. E. (2002) Sick chaperones and ageing: a perspective. Ageing Res. Rev. 1, 295-311.
61. Slavotinek, A. M. and Biesecker, L. G. (2001) Unfolding the role of chaperones and chaperonins in human disease. Trends Genet. 17, 528-535.
62. Benndorf, R. and Welsh, M. J. (2004) Shocking degeneration. Nat. Genet. 36, 547-548.
63. Casari, G., De Fusco, M., Ciarmatori, S., et al. (1998) Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 93, 973-983.
64. Hazan, J., Fonknechten, N., Mavel, D., et al. (1999) Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat. Genet. 23, 296-303.
65. Hansen, J. J., Dürr, A., Cournu-Rebeix, I., et al. (2002) Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am. J. Hum. Genet. 70, 1328-1332.
66. Atorino, L., Silvestri, L., Koppen, M., et al. (2003) Loss of m-AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia. J. Cell Biol. 163, 777-787.
67. Litt, M., Kramer, P., LaMorticella, D. M., Murphey, W., Lovrien, E. W., and Weleber, R. G. (1998) Autosomal dominant mutation of congenital cataract associated with a missense mutation in the alpha-crystallin gene CRYAA. Hum. Mol. Genet. 7, 471-474.
68. Noor, R., Mittal, S., and Iqbal, J. (2002) Superoxide dismutase - applications and relevance to human diseases. Med. Sci. Monit. 8, RA210-RA215.